{"nctId":"NCT00064077","briefTitle":"Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix","startDateStruct":{"date":"2003-05"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Recurrent Cervical Carcinoma","Stage IVB Cervical Cancer"],"count":513,"armGroups":[{"label":"Arm I (paclitaxel, cisplatin)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Drug: Paclitaxel","Other: Quality-of-Life Assessment"]},{"label":"Arm II (vinorelbine, cisplatin)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Other: Quality-of-Life Assessment","Drug: Vinorelbine Tartrate"]},{"label":"Arm III (gemcitabine, cisplatin)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Drug: Gemcitabine Hydrochloride","Other: Quality-of-Life Assessment"]},{"label":"Arm IV (topotecan, cisplatin)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Other: Quality-of-Life Assessment","Drug: Topotecan Hydrochloride"]}],"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Gemcitabine Hydrochloride","otherNames":["dFdCyd","Difluorodeoxycytidine Hydrochloride","Gemzar","LY-188011"]},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Topotecan Hydrochloride","otherNames":["Hycamptamine","Hycamtin","SKF S-104864-A","Topotecan HCl","topotecan hydrochloride (oral)"]},{"name":"Vinorelbine Tartrate","otherNames":["Biovelbin","Eunades","KW-2307","Navelbine","Navelbine Ditartrate","NVB","Vinorelbine Ditartrate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n\n  * Stage IVB, recurrent, or persistent disease\n* Not amenable to curative surgery and/or radiotherapy\n* At least 1 unidimensionally measurable lesion\n\n  * At least 20 mm by palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by spiral CT scan\n  * Biopsy confirmation required if lesion is less than 30 mm\n  * Target lesion must be outside of a previously irradiated field\n* No craniospinal metastases\n* Performance status - GOG 0-1\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times normal\n* Alkaline phosphatase no greater than 3 times normal\n* AST no greater than 3 times normal\n* Creatinine ≤ 1.2 mg/dL\n* Creatinine \\> 1.2 mg/dL but \\< 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min\n* No bilateral hydronephrosis not alleviated by ureteral stents or percutaneous drainage\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer\n* No prior malignancy whose treatment contraindicates the current study therapy\n* No concurrent clinically significant infection\n* No concurrent cytokines\n* At least 6 weeks since prior chemoradiotherapy and recovered\n* No prior chemotherapy (except when concurrently administered with radiotherapy)\n* At least 3 weeks since prior radiotherapy and recovered\n* Recovered from prior surgery","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Overall Survival (OS)","description":"Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.87","spread":null},{"groupId":"OG001","value":"9.99","spread":null},{"groupId":"OG002","value":"10.28","spread":null},{"groupId":"OG003","value":"10.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Response Using RECIST Version 1.0","description":"RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"53","spread":null}]},{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Progression-free Survival (PFS)","description":"Progression-free survival (PFS) was defined as the period from study entry until disease progression, death, or the last date of contact. Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.82","spread":null},{"groupId":"OG001","value":"3.98","spread":null},{"groupId":"OG002","value":"4.70","spread":null},{"groupId":"OG003","value":"4.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)","description":"The FACT-Cx TOI is a scale for assessing general QOL of cervical cancer patients.consisting of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Cervical Cancer subscale (15 items). Each item in the FACT-Cx TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The score is calculated as the sum of the subscale scores if more than 80% of the FACT-Cx TOI items provide valid answers and all of the component subscales have valid scores. The score ranges 0-116 with a large score suggesting better QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":"17.6"},{"groupId":"OG001","value":"69.1","spread":"18.6"},{"groupId":"OG002","value":"67.9","spread":"19.5"},{"groupId":"OG003","value":"68.1","spread":"19.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"17.6"},{"groupId":"OG001","value":"65.5","spread":"15.8"},{"groupId":"OG002","value":"65.3","spread":"18.2"},{"groupId":"OG003","value":"66.2","spread":"16.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":"16.5"},{"groupId":"OG001","value":"66.6","spread":"17.4"},{"groupId":"OG002","value":"64.5","spread":"16.5"},{"groupId":"OG003","value":"68.4","spread":"15.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":"16.6"},{"groupId":"OG001","value":"69.9","spread":"18.8"},{"groupId":"OG002","value":"68.6","spread":"19.5"},{"groupId":"OG003","value":"70.9","spread":"17.9"}]}]}]},{"type":"SECONDARY","title":"Pain, Assessed by Brief Pain Inventory","description":"Single item from the Brief Pain Inventory (BPI) assessing \"worst pain\" in the past 24 hours, on a 0-10 scale with a higher score indicating more pain than a low score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"2.8"},{"groupId":"OG001","value":"3.9","spread":"3.2"},{"groupId":"OG002","value":"3.3","spread":"3.0"},{"groupId":"OG003","value":"3.6","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"2.9"},{"groupId":"OG001","value":"3.5","spread":"2.8"},{"groupId":"OG002","value":"3.4","spread":"3.0"},{"groupId":"OG003","value":"3.6","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"3.1"},{"groupId":"OG001","value":"4.0","spread":"2.7"},{"groupId":"OG002","value":"3.5","spread":"3.0"},{"groupId":"OG003","value":"2.5","spread":"3.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.0"},{"groupId":"OG001","value":"3.2","spread":"2.9"},{"groupId":"OG002","value":"3.7","spread":"3.0"},{"groupId":"OG003","value":"2.9","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).","description":"The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"2.9"},{"groupId":"OG001","value":"13.5","spread":"3.4"},{"groupId":"OG002","value":"14.2","spread":"2.9"},{"groupId":"OG003","value":"14.1","spread":"3.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":"3.2"},{"groupId":"OG001","value":"13.3","spread":"3.6"},{"groupId":"OG002","value":"13.7","spread":"3.5"},{"groupId":"OG003","value":"14.2","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"3.5"},{"groupId":"OG001","value":"13.1","spread":"3.7"},{"groupId":"OG002","value":"14.1","spread":"3.0"},{"groupId":"OG003","value":"14.4","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"5.2"},{"groupId":"OG001","value":"11.4","spread":"4.7"},{"groupId":"OG002","value":"12.3","spread":"3.7"},{"groupId":"OG003","value":"13.1","spread":"3.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":103},"commonTop":["Anemia","Leukopenia","Neutropenia","Fatigue","Other Gastrointestinal"]}}}